pharmacokinetics and pharmacodynamics
Recently Published Documents


TOTAL DOCUMENTS

4253
(FIVE YEARS 724)

H-INDEX

120
(FIVE YEARS 14)

Abstract Number of people over 65 years is continuously increasing and represents an ever growing proportion of population even in Hungary. Medical treatment of the elderly implies a massive burden for the healthcare system. Special knowledge is required to provide an appropriate medical care for the elderly. During the ageing process, several changes accumulate in the body and several chronic diseases develop. Function of parenchymal organs is impaired, healing process is slower, clinical manifestations of diseases are not so prominent, the diagnosis is often difficult to establish. Moreover, treatment possibilities also differ, because pharmacokinetics and pharmacodynamics of drugs are different from that of young patients. Communication with older patients is also cumbersome, participation of a relative or caregiver at consultation can be useful. Cardiovascular diseases remain the leading cause of death of adults over the age of 65. Among these diseases congestive heart failure, coronary artery diseases, hypertension, atrial fibrillation have the greatest significance.


2022 ◽  
pp. 30-35
Author(s):  
Rowan Elkeshawi ◽  
Katherine Maddox ◽  
Andriana Xenophontos ◽  
Kyle Hampson

The delivery of safe and effective healthcare to pediatric and neonatal patients presents unique challenges to the medication-use system. The diversity of patients within this population and the consequences of ontogeny on pharmacokinetics and pharmacodynamics directly impact the safe use of medications in children and increase the risk of adverse drug events.1 This review will explore the medication-use system for hospitalized children and neonates, discuss vulnerabilities within this system, and provide examples of advancements made to improve the pediatric medication-use system.


2022 ◽  
Author(s):  
Anna V. Reznik

The aim of this chapter is to structure current information clarifying the most disputable issues of botulinum neurotoxin type A (BoNT/A) pharmacology after systemic (botulism) impact and local medical application. Botulinum neurotoxin (BoNT) pharmacological features evaluated open ways to study factors affecting its biological activity: to extend/shorten its effect duration, to increase/decrease BoNT sensitivity in specific patient populations. The chapter presents unique molecular mechanisms underlying BoNT/A pharmacokinetics and pharmacodynamics: entering the body, distribution, receptor binding, translocation, mediator release suppression, zinc metabolism as well as factors affecting body sensitivity to BoNT at each of those stages. The specific biological effects of BoNT/A, which may underlie its analgesic, anticancer and anti-inflammatory effects, are described. Botulinum neurotoxin pharmacokinetics and pharmacodynamics features discussed herein represent significant clinical relevance since they determine botulinum treatment safety and effectiveness. And also they open ways to develop both BoNT-based therapies and anti-botulinic agents.


Author(s):  
L. V. Fedina ◽  
I. N. Sychev ◽  
D. A. Sychev

In recent years, there has been a trend towards increased prescribing of direct-acting oral anticoagulants (DOACs) due to favourable pharmacokinetics and pharmacodynamics without the need for regular coagulation monitoring. However, recent studies have documented individual variability in plasma DOAC levels. DOAC pharmacogenetics is a relatively new area of research. There is a need to understand the role of pharmacogenetics in the adaptation of anticoagulant therapy according to a patient’s genetic characteristics. This scientific review of current data on the impact of different gene polymorphisms on apixaban pharmacokinetics broadens the understanding of the clinical relevance of genotyping for treatment efficacy and safety.


2022 ◽  
Vol 226 (1) ◽  
pp. S744-S745
Author(s):  
Rupsa C. Boelig ◽  
Edwin Lam ◽  
Ankit Rochani ◽  
Gagan Kaushal ◽  
Walter Kraft

Sign in / Sign up

Export Citation Format

Share Document